docwirenews.com
Cure8 news brief
Why This Matters
Up to one-third of people with IBD in clinical remission still have IBS-like symptoms that reduce quality of life and are not helped by anti-inflammatory treatments.
This review indicates there’s not yet strong proof that dietary, behavioral, or drug therapies reliably relieve these symptoms, so patients and clinicians may need to weigh options individually and watch for better evidence from future trials.
Who Should Pay Attention
Adults with IBD in remission who have ongoing IBS-like symptoms, gastroenterology clinicians, clinical researchers designing symptom-directed IBD trials, and dietitians/mental-health providers working on gut–brain interventions.
Study Snapshot
Story typeResearch news
Evidence typeSystematic Review or Meta Analysis
Source depthFull source text
What To Know
This analysis looked specifically at adults with IBD in remission who still have persistent IBS-like symptoms — a common unmet need. Researchers categorized interventions as dietary, behavioral (gut-brain-targeted), or pharmacologic and pooled trial results using standard meta-analytic methods.
The clearest takeaway is that current randomized-trial evidence is insufficient to recommend one symptom-directed therapy as clearly superior.
Dietary approaches showed the largest pooled symptom change but the evidence certainty was low; behavioral therapies had smaller benefits with low certainty; pharmacologic data were limited and from small, isolated trials.
The authors emphasize the methodological limits of existing trials (high risk of bias, subjective endpoints, heterogeneity) and recommend larger, rigorously blinded trials with standardized endpoints to identify effective treatments.
Keep In Mind
Findings are based on 13 RCTs up to October 2025 and were rated low certainty overall due to heterogeneity, imprecision, and high risk of bias (many trials unblinded and using subjective endpoints). This analysis does not test new treatments itself; it summarizes existing trial evidence and calls for better-designed studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 8, 2026, 9:51 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
From Dysbiosis to systemic health: Microbiome modulation as a unified therapeutic framework.
The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...
Global research trends in enteric nervous system and gut microbiota: a bibliometric analysis (2005-2025).
The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...
Dynamic precision therapy in chronic gastrointestinal diseases: A focus on gastroesophageal reflux disease and inflammatory bowel disease-A narrative review and conceptual perspective.
The review lays out a multidimensional precision-care model that could help make IBD treatment more personalized, reduce unnecessary continuous medication, and use biomarker and technology-driven adjustments to manage...